Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript Summary
Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript Summary
Gross The following is a summary of the Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript:
以下是evolus公司（EOLS）2024年第三季度業績會議呼叫記錄摘要:
Financial Performance:
財務表現：
Evolus achieved a 33% increase in year-to-date revenue compared to 2023.
Q3 2024 net revenue was $61 million, up 22% from the previous year.
Gross margin for Q3 2024 was 68.9%, with an adjusted gross margin of 70.2%.
Non-GAAP operating loss in Q3 2024 was $6.7 million due to seasonally lower revenue.
與2023年相比，evolus的年度營業收入增長了33%。
2024年第三季度淨營業收入爲6100萬美元，較去年同期增長22%。
2024年第三季度的毛利率爲68.9%，調整後的毛利率爲70.2%。
由於季節性營業收入較低，2024年第三季度的非GAAP運營虧損爲670萬美元。
Business Progress:
業務進展：
Launched Estyme in Europe and preparing for the US launch of Evolysse.
Added over 600 purchasing accounts in Q3, maintaining a reorder rate over 70%.
Launched Club Evolus, a subscription-based consumer membership program.
在歐洲推出了Estyme，併爲美國上市evolysse做準備。
在第三季度新增了600多個採購帳戶，重新訂購率保持在70%以上。
推出了Evolus俱樂部，一個基於訂閱的消費會員計劃。
Opportunities:
機會：
Expected revenue growth driven by neurotoxin business and new injectable HA gels beginning in 2025, targeting $700 million in net revenue by 2028.
Evolus is capitalizing on a total addressable market expected to grow from $6 billion now to approximately $10 billion by 2028.
預計由神經毒素業務和2025年開始的新注射式HA凝膠帶來的收入增長，目標是到2028年達到70000萬元的淨收入。
Evolus正在利用預計從現在的60億美元增長到2028年約100億美元的總可尋址市場。
Risks:
風險：
Seasonal reduction in revenue typically seen in Q3 affects the financial results.
Possible impacts from the upcoming market entry of competitor Hugel.
第三季度通常出現的營業收入季節性減少會影響財務結果。
競爭對手Hugel即將進入市場可能會產生影響。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情，請參閱IR網站。本文僅供投資者參考，不具有任何指導或推薦建議。
